Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

- Read more about Medicine effective in cancer through plant virus nanoparticals
In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo.
- Read more about DNA scrunching may lead to a new class of antiviral drugs one day
Evidence of DNA "scrunching" may one day lead to a new class of drugs against viruses, according to a research team from the Perelman School of Medicine at the University of Pennsylvania, the Georgia Institute of Technology, and Columbia University. The team is led by Stephen C. Harvey, PhD, an adjunct professor in the department of Biochemistry and Biophysics at Penn. The scientists report in The Journal of Physical Chemistry B that DNA may go through a repetitive cycle of contraction and elongation, or as they put it, "scrunching," to generate the forces required to drive the DNA into a virus during replication. A better understanding of viral reproduction could be the basis of new ways to fight infectious pathogens.
- Read more about Gonorrhea negative patients also receive antibiotics
A study of emergency department (ED) patients with symptoms of gonorrhea or chlamydia found that three in four patients who were treated with antibiotics actually tested negative for these sexually transmitted diseases (STDs), according to a new study presented at the 43rd Annual Conference of the Association for Professionals in Infection Control and Epidemiology (APIC).
- Read more about Novartis phase III study of Tafinlar + Mekinist combo therapy shows significant survival benefit
Novartis announced data from a phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar (dabrafenib) + Mekinist (trametinib) compared to Tafinlar monotherapy.
- Read more about Novartis presents new scientific evidence for at EULAR 2016
Novartis announced that it will present 33 scientific abstracts at the Annual European Congress of Rheumatology (EULAR 2016) in London, UK. This includes new long-term analyses suggesting Cosentyx® (secukinumab) may lead to higher responses than Humira (adalimumab) in improving the signs and symptoms of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) at 52 weeks. These analyses are from two studies using the Matching-Adjusted Indirect Comparisons (MAIC) method. MAIC is a valid and accepted method for comparative effectiveness research.
- Read more about Roche’s Avastin + Tarceva receives EU approval
Roche announced that the European Commission has approved the use of Avastin® (bevacizumab) in combination with Tarceva® (erlotinib) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)-activating mutations.
- Read more about Allergan Announces FDA Approval of BYVALSON™ (nebivolol and valsartan)
Allergan plc announced the approval of BYVALSON™ (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. Food and Drug Administration (FDA) for the treatment of hypertension to lower blood pressure. BYVALSON is the first and only fixed-dose combination (FDC) of a beta blocker (BB) and angiotensin II receptor blocker (ARB) available in the U.S.
- Read more about Amgen launches Kyprolis Central, an online media resource
Amgen announced the launch of Kyprolis Central, an online media resource about the impact of living with relapsed or refractory multiple myeloma. Intended to drive awareness of a rare blood cancer that is increasingly becoming more prevalent in the United States (US), Kyprolis Central provides real-life stories from relapsed multiple myeloma patients, as well as educational materials and third party resources.

[adsense:336x280:8701650588]
- Read more about FDA give Complete Response Letter to Adamis Pharmaceuticals Epinephrine Pre-Filled Syringe NDA
Adamis Pharmaceuticals Corporation announced that after the close of the stock markets on June 3, 2016 it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) product. PFS is for the emergency treatment of acute anaphylaxis, which is a severe allergic reaction. A CRL is issued by the FDA's Center for Drug Evaluation and Research when it has
- Read more about Merck & Lilly products show positive results in Early-Phase Immuno-Oncology Studies
Eli Lilly and Company announced that clinical study data from two of its ongoing immuno-oncology clinical collaborations with Merck were presented this weekend at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO). Specifically, data were presented from two early-phase trials evaluating ALIMTA® (pemetrexed)-plus-carboplatin and CYRAMZA® (ramucirumab), respectively, in combination with Merck's KEYTRUDA® (pembrolizumab), in patients with non-small cell lung cancer (NSCLC).